Wilson Sonsini Goodrich & Rosati advised Curon Biopharma on the deal. Curon Biopharma, a Shanghai based clinical-stage biopharmaceutical company, acquired exclusive rights to Tenalisib from Rhizen…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
